Advancement of Biomarker Discovery and Validation through the HUPO Plasma Proteome Project
Open Access
- 1 January 2004
- journal article
- research article
- Published by Wiley in Disease Markers
- Vol. 20 (3) , 131-134
Abstract
The Human Proteome Organization (HUPO) Plasma Proteome Project has mounted a Pilot Phase focussed on key problems essential for standardization of specimen collection, specimen handling, choice of fractionation and analysis technologies, and search engines and databases for protein identifications. This international collaboration will lay the groundwork for many large‐scale clinical and epidemiological studies of health and disease.Keywords
Funding Information
- National Institutes of Health (CA84982, MEDC-238)
- Johnson Family Foundation (CA84982, MEDC-238)
- Pfizer (CA84982, MEDC-238)
- BD Diagnostics (CA84982, MEDC-238)
- Abbott Fund (CA84982, MEDC-238)
- Amersham (CA84982, MEDC-238)
- Bristol Myers Squibb (CA84982, MEDC-238)
- Novartis (CA84982, MEDC-238)
- Procter & Gamble (CA84982, MEDC-238)
- Invitrogen (CA84982, MEDC-238)
- Ciphergen (CA84982, MEDC-238)
- Dade Behring (CA84982, MEDC-238)
- Michigan Life Sciences Corridor (CA84982, MEDC-238)